2 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow Malignancy: new trials by email Literature Review of Malignancy trials Research Report on Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors BMS-986226, Nivolumab, Ipilimumab - Cancer, Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 80 | 2017-09-01 | 2023-02-28 |
| Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants Thymoglobulin (rATG) - Malignancy, Metabolic Disease | Phase 2 | Terminated | The Hospital for Sick Children | 30 | 2009-11-01 | 2019-11-04 |
Neoplasms (2) · Genetic Diseases, Inborn (1) · Metabolic Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Nutritional and Metabolic Diseases (1)
Antilymphocyte Serum (1) · Ipilimumab (1) · Nivolumab (1) · Tetanus Toxoid (1) · thymoglobulin (1)
Bristol-Myers Squibb (1) · The Hospital for Sick Children (1)
Canada (2) · Spain (1) · Switzerland (1) · United States (1)
Tal Schechter-Finkelstein, MD (1)
2017 (1)